Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was discontinued following product approval.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Post-approval study of the safety and effectiveness of NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles 410 FM, FF, MM, or MF) for breast augmentation, reconstruction, or revision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Augmentation | Experimental | Women undergoing breast augmentation. |
|
| Reconstruction | Experimental | Women undergoing breast reconstruction. |
|
| Revision-Augmentation | Experimental | Women undergoing revision of previous breast augmentation. |
|
| Revision-Reconstruction | Experimental | Women undergoing revision of previous breast reconstruction. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anatomically shaped silicone gel-filled breast implants | Device | Surgical implant |
|
| Measure | Description | Time Frame |
|---|---|---|
| Subject Satisfaction With Breast Implants on a 5-Point Scale | Subject satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for subject's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the subject reports different responses for the left and right breasts. | 5 years |
| Investigator Satisfaction With Breast Implants on a 5-Point Scale | Investigator satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for Investigator's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the Investigator reports different responses for the left and right breasts. | 5 years |
| Local Complications | Local complications are the cumulative complications occurring in at least 5% of subjects in 1 or more cohorts over the duration of the study. The Kaplan-Meier risk rate is presented. | 5 years |
Not provided
Not provided
Inclusion Criteria:
For entry in this study, subjects must have been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study under the inclusion criteria listed below and received NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants Styles 410 FM, FF, MM, or MF in 1 (for unilateral breast reconstruction or revision) or both breasts.
Exclusion Criteria:
For entry in this study, subjects must have been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study and met the exclusion criteria listed below but not received any NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled 410 X- or L-Style Breast Implants
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan Medical | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eugene | Oregon | United States |
Not provided
The study was discontinued following product approval.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Augmentation | Women undergoing breast augmentation. |
| FG001 | Revision-Augmentation | Women undergoing revision of previous breast augmentation. |
| FG002 | Reconstruction | Women undergoing breast reconstruction. |
| FG003 | Revision-Reconstruction | Women undergoing revision of previous breast reconstruction. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Augmentation | Women undergoing breast augmentation. |
| BG001 | Revision-Augmentation | Women undergoing revision of previous breast augmentation. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Subject Satisfaction With Breast Implants on a 5-Point Scale | Subject satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for subject's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the subject reports different responses for the left and right breasts. | Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants, who completed the 5 year follow-up visit, and had data at the time point. | Posted | Number | Subjects | 5 years |
|
Not provided
Adverse event (AE) data experienced by ≥5% of subjects are recorded as an outcome measure.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Augmentation | Women undergoing breast augmentation. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Allergan Inc., | Allergan, Inc | clinicaltrials@allergan.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| BG002 | Reconstruction | Women undergoing breast reconstruction. |
| BG003 | Revision-Reconstruction | Women undergoing revision of previous breast reconstruction. |
| BG004 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Revision-Augmentation |
Women undergoing revision of previous breast augmentation. |
| OG002 | Reconstruction | Women undergoing breast reconstruction. |
| OG003 | Revision-Reconstruction | Women undergoing revision of previous breast reconstruction. |
|
|
| Primary | Investigator Satisfaction With Breast Implants on a 5-Point Scale | Investigator satisfaction with each breast implant is assessed on the following 5-point scale: (Definitely Satisfied, Somewhat Satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, and Definitely Dissatisfied). Satisfaction is reported for Investigator's assessing satisfaction as definitely satisfied and somewhat satisfied. The worst response is used if the Investigator reports different responses for the left and right breasts. | Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants, who completed the 5 year follow-up visit, and had data at the time point. | Posted | Number | Subjects | 5 years |
|
|
|
| Primary | Local Complications | Local complications are the cumulative complications occurring in at least 5% of subjects in 1 or more cohorts over the duration of the study. The Kaplan-Meier risk rate is presented. | Evaluable population: all enrolled subjects implanted with the NATRELLE 410 original style implants who completed the 5 year follow-up visit. | Posted | Number | 95% Confidence Interval | Percentage of Subjects | 5 years |
|
|
|
| 0 |
| 1,939 |
| 0 |
| 1,939 |
| EG001 | Revision-Augmentation | Women undergoing revision of previous breast augmentation. | 0 | 693 | 0 | 693 |
| EG002 | Reconstruction | Women undergoing breast reconstruction. | 0 | 751 | 0 | 751 |
| EG003 | Revision-Reconstruction | Women undergoing revision of previous breast reconstruction. | 0 | 428 | 0 | 428 |
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
| Somewhat Satisfied |
|
| Asymmetry |
|